Recently, we found that USP22 was frequently overexpressed in lung cancer and knockdown of USP22 suppressed CSC maintenance, in vivo angiogenesis, growth, and metastasis of KRAS mutant lung cancer, and significantly sensitized these cells to cisplatin and irradiation independent p53 status [14–16]. Here, USP22 is linked to lung carcinoma.